Novel Topical Treatments for Itch Rami H. MahmoudOmar MahmoudGil Yosipovitch Review Open access 13 April 2024 Pages: 829 - 840
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities Luca PotestioNello TommasinoMatteo Megna Review Open access 09 April 2024 Pages: 841 - 852
Virtual Learning Decreases the Carbon Footprint of Medical Education Divya SharmaJulianne RizzoJenny E. Murase Original Research Open access 26 March 2024 Pages: 853 - 859
Inconsistent Associations Between Risk Factor Profiles and Adjuvant Radiation Therapy (ART) Treatment in Patients with Cutaneous Squamous Cell Carcinoma and Utility of the 40-Gene Expression Profile to Refine ART Guidance Brent R. MoodyAaron S. FarbergWalton A. Taylor Original Research Open access 23 March 2024 Pages: 861 - 873
Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis Lawrence F. EichenfieldLinda F. Stein GoldJuliana M. Canosa Original Research Open access 28 March 2024 Pages: 875 - 892
Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment Chun-Xia HeChao WuHong-Zhong Jin Original Research Open access 14 March 2024 Pages: 893 - 906
Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study Ying LiChengzhi LvYuling Shi Original Research Open access 27 March 2024 Pages: 907 - 918
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus Luigi GargiuloLuciano IbbaAlessandra Narcisi Original Research Open access 21 March 2024 Pages: 919 - 932
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies April ArmstrongAlvaro González-CanteroAndrew Blauvelt Original Research Open access 23 March 2024 Pages: 933 - 952
Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study Michela StaraceFrancesca PampaloniZoe Apalla Original Research Open access 10 April 2024 Pages: 953 - 970
Utilising SNP Association Analysis as a Prospective Approach for Personalising Androgenetic Alopecia Treatment Manuel Pacareu FrancèsLaura Vila-VecillaGustavo Torres de Souza Original Research Open access 31 March 2024 Pages: 971 - 981
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis Tiago TorresAnne Sohrt PetersenJosé Manuel Carrascosa Original Research Open access 13 April 2024 Pages: 983 - 992
The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016 Sissel Brandt Toft SørensenPrethibha GeorgeVera Ehrenstein Original Research Open access 16 April 2024 Pages: 993 - 1006
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60 Alexander EgebergJason E. HawkesApril Armstrong Original Research Open access 22 April 2024 Pages: 1007 - 1018
Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis Tina BhutaniJohn KooJ. Gabriel Vasquez Brief Report Open access 04 April 2024 Pages: 1019 - 1025
Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries Sergio Vañó-GalvánAlexander EgebergAnthony Bewley Brief Report Open access 21 March 2024 Pages: 1027 - 1037
Clinical Characteristics and Therapeutic Aspects of Blaschko Linear Psoriasis Ling ChenYufan ChengZhu Shen Brief Report Open access 05 April 2024 Pages: 1039 - 1048
Atypical Fibroxanthoma Treated with a Topical Combination of Imiquimod, Tazarotene, and 5-Fluorouracil William J. NahmEvangelos V. BadiavasJohn Shen Case Report Open access 12 March 2024 Pages: 1049 - 1056
Acute Systemic Toxicity Caused by Topical Application of EMLA Cream on a Leg Ulcer: Case Report and Review of Literature Sarah Marie HoffmannAnna Luisa HartmannChristoph Mathis Schempp Case Report Open access 03 April 2024 Pages: 1057 - 1062
Letter to the Editor Regarding: Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study Ruiyao HuYue WangChen Li Letter Open access 09 April 2024 Pages: 1063 - 1065
Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study” A. David Burden Letter Open access 05 April 2024 Pages: 1067 - 1069